Status epilepticus (SE) is typically defined as a prolonged self-sustaining seizure or repeated seizures showing an incomplete recovery between them. SE represents a medical emergency often associated with significant disability, morbidity, and mortality. Despite the clinical impact, the mechanisms underlying the transition from self-limited seizures to protracted, medically refractory seizures are not completely understood. About 40% of patients in established SE are refractory to antiepileptic drugs (first-line treatment); therefore, there is a need for more efficacious drugs. In this review, we focused on the current knowledge about the involvement of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors during SE, the preclinical efficacy of its antagonists, and the currently published clinical studies involving drugs with this mechanism of action.
networks, depending on the type and duration of seizures." 1 Usually, t1 represents the time after which seizure activity should be considered as "continuous seizure activity." Moreover, this is also the time when the treatment should be initiated. SE represents a severe neurological emergency associated with significant mortality and morbidity. SE has an incidence of about 10-60 cases per 100 000/y. The overall mortality of SE was estimated at around 20%. [2] [3] [4] Recently, Kortland et al 5 published data concerning the costs due to SE in 3 different German University Hospitals. They have studied 341 admissions in 316 patients. Mean costs of hospital treatment were €14 946 per subject per admission. Course of SE induces a significant enhancement on mean costs, which were related to the type of SE, for instance €8314 in nonconvulsive SE, €13 399 in resistant SE, and €50 488 in superresistant SE. Furthermore, data extrapolation to the whole of Germany indicates that SE produces hospital costs greater than €200 million per year. Despite the clinical impact, the mechanisms underlying the transition from self-limited seizures to prolonged, medically refractory seizures are not fully understood. Using animal models, previous research articles have initially described alterations in c-aminobutyric acid (GABA) A receptors that might explain the resistance of SE to benzodiazepines leading to refractory SE (RSE) and superrefractory SE (SRSE). 6 Specifically, it is now clear that a loss of inhibitory GABA A neuronal activity coupled to sustained glutamate-mediated excitatory activity due to alterations in N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors is chiefly involved in SE. 3, [7] [8] [9] [10] In the lithium-pilocarpine rat model of SE, the timing of functional loss of postsynaptic GABA A receptors due to internalization of the receptor into the cytoplasm appears~1 hour after seizure onset. 7 In the clinical setting, SE is divided into 4 successive stages according to response to drug treatments: early, established, refractory, and superrefractory. 11 To date, the first-line treatment for early SE (stage I) is based on the intravenous (iv) injection of benzodiazepines (eg, diazepam, lorazepam, clonazepam, and midazolam), which potentiate inhibitory neurotransmission by binding to the GABA A receptor complex. Benzodiazepines can control SE in about 60% of all patients, whereas the remaining cases are resistant to benzodiazepines (established SE or stage II). In established SE, several others intravenous antiepileptic drugs (AEDs), with different mechanisms of action, including phenytoin, valproate, levetiracetam, phenobarbital, and lacosamide, are often used, without clear indications to choose one over the other, as alternative second-line drugs for the management of SE. About 40% of patients with established SE are refractory to AEDs (refractory SE or stage III), 3, 12 and in these cases admission to an intensive care unit and treatment with intravenous anesthetics such as midazolam, propofol, barbiturates, and ketamine is needed while other treatments should also be considered (eg, magnesium, immunotherapy). Nevertheless, in many cases, despite all the efforts, it is not possible to prevent severe acute systemic and long-term neuronal consequences. 3, [13] [14] [15] Furthermore, in the last 2 stages, off-label treatment and nonpharmacological therapies are used (eg, ketogenic diet, vagus nerve and deep brain stimulations, and hypothermia). It is therefore clear that it would be worthwhile to test the hypothesis of whether compounds with different mechanisms of action would be efficacious. In particular, the availability of AEDs able to increase SE response after the failure of first-line treatment and before the need of anesthetizing agents would be of paramount importance. By now, among the potential drugs and targets currently studied, those regulating excitatory transmission, blocking glutamate receptors of the AMPA subtype, have had relatively little consideration even though AMPA receptors (AMPARs) have been recognized to have a key role in ictogenesis and epileptogenesis. [16] [17] [18] [19] Competitive and noncompetitive AMPAR antagonists have antiseizure and antiepileptogenic effects in a broad range of in vitro and in vivo preclinical models. 16, 17, 20 AMPARs are widespread in the mammalian central nervous system (CNS), including areas relevant for seizure generation, and are largely postsynaptic. 19, 21 Therefore, AMPAR antagonists represent a group of compounds with mechanisms and sites of action different from those of currently available drugs used for SE management. 3, 16 Notably, also the other ionotropic glutamate receptors (ie, NMDA and kainate) and metabotropic receptors are involved in epilepsy, and some of them in SE; for a review see Dingledine 22 and Nicoletti et al. 23 Here, we review the current knowledge about the involvement of AMPARs during SE, the preclinical efficacy of AMPAR antagonists, and the currently published clinical studies involving drugs with this mechanism of action.
| AMPA RECEPTORS IN STATUS EPILEPTICUS
Ionotropic glutamatergic receptors contribute to seizure sustenance and SE-induced cell death. 24, 25 Recently the plasticity of glutamatergic transmission during SE has been studied. Due to the central function of AMPA glutamate (Glu) receptors in fast excitatory neurotransmission, it is not surprising that the prolonged activation of these receptors plays a prominent role in the development and progression of epileptic seizures. Furthermore, alterations in the physiology and pharmacology of AMPARs are also linked to an abnormal electrical neuronal activity. 16 AMPA receptors are formed as heterotetramers from combinations of the protein subunits GluA1, GluA2, GluA3, and GluA4, which are assembled to generate an ion channel with different physiological properties. Among these subunits, GluA2 has been shown to be particularly important for the functional properties of heteromeric AMPA receptors, regulating both channel rectification and ion permeability. Based on this background, many studies have been focused primarily on the expression levels of the GluA2 protein subunit. 21, 26, 27 In fact, during the early phases of postnatal development, AMPARs are permeable both to Na + and Ca
2+
. This property is related to the absence of an edited GluA2 subunit, leading to an augmented neuronal excitability. In detail, during early brain development, several neurons switch from GluA2-lacking to GluA2-containing synaptic AMPARs. Particularly, it has been observed that the presence of unaltered GluA2 subunit was fundamental to exclude Ca 2+ permeability through AMPARs. 27, 28 Indeed, channels consisting only of GluA1, GluA3, and GluA4 subunits display a wide inwardly rectifying current-voltage relation and Ca 2+ permeability. 27 Therefore, during early development, when the brain is extremely susceptible, unedited GluA2 subunit expression results in an increase of Ca 2+ permeability through AMPARs, reducing seizure threshold. 29 Such phenomena could also be associated with the epileptogenic process. 30 Moreover, GluA2-lacking AMPA receptors promote excitotoxicity and neurodegeneration by means of Ca 2+ entry in neurons that normally express Ca 2+ -impermeable channels contributing to, or causing, delayed cell death in response to endogenous glutamate. 21, 31, 32 Relevant plastic changes in the expression and functioning of AMPARs, and particularly in their subunit composition, have been demonstrated already during early stages of SE in several animal models including the lithium-pilocarpine, 33 ,34 pilocarpine-, 35 kainate-induced SE 36,37 (Table 1) .
It is notable that most of these models also represent animal models of epileptogenesis; considering the aim of this review, we only include discussion of relevant changes within the first 24 hours after the initiation of SE, which might be considered relevant to this phenomenon, although some processes may also be linked to epileptogenesis. 38 Some of these studies have underscored how changes in the expression of AMPARs could be subunit and brainregion specific. 33, 34 However, these studies focused particularly on temporal lobe regions and above all on the hippocampus and piriform cortex, describing seemingly contradictory results with augmented, reduced, or unchanged AMPARs subunit expression. Such variability could be due to the different experimental procedures used to induce SE as well as to the employment of different strain and/or ages of animals. Recently, early lasting changes in AMPAR features at transcriptional and translational levels were identified in a rat model of pilocarpineinduced SE (250 mg/kg, ip). After 3 hours of pilocarpineinduced SE in rats, a disorganization of glutamatergic neuronal pathway as well as an alteration of AMPAR subunits expression (increased GluA2 and reduced GluA1, GluA3, and GluA4 expression) has been discovered. Such modifications seem to be relevant in cerebral cortex and hippocampal regions. According to this study, the reduction of AMPARs' postsynaptic excitatory response to glutamate, observed after pilocarpine-induced SE, led to neuronal protection from the excitotoxic damage. 39 These results are in contrast with the current literature, indicating a reduction in GluA2 subunit expression. However, one of the findings was altered messenger RNA (mRNA) expression of the various subunits, which were generally increased (except for GluA2) rather than reduced; furthermore, glutamate response was not evaluated, and therefore, the data presented do not allow us to conclude that the AMPAR response was reduced. Of interest, Lopes et al 40 have also observed a modulation of AMPAR phosphorylation as well as mRNA expression of NMDA receptors and glutamate transporters in the hippocampus and cerebral cortex of rats at different time points after pilocarpine induced-SE (280 mg/kg; ip), which represents in the chronic phase an animal model of temporal lobe epilepsy with hippocampal sclerosis (TLE-HS). In detail, biochemical assays were carried out in these brain regions respectively at 1, 3, and 12 hours (acute phase), 5 days (latent phase), and 50 days (chronic phase) following SE (the last 2 time points should not be considered part of SE). During the acute phase (within 12 hours), an increase in the phosphorylation of GluA1-Ser 831 (which regulates AMPAR inclusion into the synapse) was observed in the hippocampus; in contrast, a decrease in the phosphorylation of GluA1-Ser 845 (regulating AMPAR internalization) was recognized in the chronic period (not during SE). Conversely, the phosphorylation of GluA1-Ser 845 in the cerebral cortex was enhanced in the acute phase. According to these results, the authors have concluded that a time-and structure-dependent alteration of glutamatergic transmission occurs also after pilocarpine induced-SE. Such alterations could be associated with SE, epileptogenesis, and seizure threshold alteration in TLE-HS. 40 Recently, Malkin et al 41 have reported similar alterations both in hippocampus and in extratemporal lobe regions, specifically in the medial prefrontal cortex measured up to 7 days following Li-pilocarpine-induced SE. In the hippocampus of epileptic rats, GluA1 and GluA2 mRNA expression was reduced at 24 hours after SE; however, their ratio was not modified and their expression was normalized at 72 hours (long after SE termination). Moreover, the epileptic rats in comparison to control rats have shown a widely decreased GluA2 mRNA expression in prefrontal cortex but not in temporal cortex. Such reductions started within 3 hours after pilocarpine-induced SE and lasted for at least 7 days. According to the authors, these changes, which are brain region and subunit specific, widely enhanced the GluA1/GluA2 expression ratio in prefrontal cortex relative to in hippocampus, as a consequence of GluA2-lacking AMPA receptors. 41 Notably, Szczurowska et al 42 reported an altered level of GluA2 mRNA and GluA2 protein expression, in different brain regions such as prefrontal cortex and hippocampus, early after SE elicited by injection of pilocarpine (40 mg/kg, ip) in rats at postnatal age of 12 days (P12). Subsequently, SE was stopped, after 1.5 hours of continuous seizures, by the administration of paraldehyde (0.07 mL/kg, ip). This study was conducted throughout the development, at 3 hours (protein level), as well as at 3-, 6-, 13-, and 60 days (P12, P15, P18, P25, and P72, respectively) after SE. Considering only the 3-hour time point, GluA2 protein levels are significantly reduced in the ventral hippocampus but not all other areas considered (ie, dorsal hippocampus, cortex, and thalamus). In contrast, considering other time points in the latent phase (ie, not during SE), it seems that both neocortex and dorsal hippocampus can trigger endogenous antiepileptic mechanisms, including upregulation of GluA2 expression and low Ca 2+ permeability, after an elevated excitability with the aim of avoiding further brain damage. 42 Overall, animal data show that seizures can cause rapid dynamic alterations in AMPA receptor subunit composition and function (mediated by trafficking and endocytosis). GluA2 subunit expression and therefore Ca 2+ permeability of AMPARs appear to be modified both in temporal and in extratemporal brain regions of several animal models of SE. These studies indicate that AMPA-mediated neurotransmission during SE is associated with an increased surface expression of GluA1 and a decreased expression of GluA2 subunit. Of interest, the subunit composition of glutamate and GABA receptors was also assessed in brain samples from subjects affected by several types of SE. 43 Particularly, the following has been demonstrated: (1) an augmented GluA1/GluA2 AMPAR ratio in electrical SE during sleep; (2) an augmented GluN2B/GluN2A NMDA receptor ratio in electrical SE in sleep as well as in refractory convulsive SE; and (3) an increased GABA a2/a1 ratio in refractory convulsive SE. Finally, in subjects with abnormalities of cortical development, an increase in GluA1/GluA2, GluN2B/GluN2A, and a2/a1 ratio have been discovered when compared to controls. Therefore, this study has confirmed what has been discovered in animal models, suggesting also that the regulation of different receptor subunit expression could be considered an adjunctive potential target for the management of SE. Finally, of particular interest is a phenomenon defined as secondary epileptogenesis or "mirror focus," which was confirmed both in humans and in an experimental model of SE. 44 In the control and UBP 301-treated rats, seizure onset was recorded mainly in the contralateral hippocampus after a few minutes of kainate injection, whereas CNQX-treated rat seizures have been recorded in the ipsilateral hippocampus. According to the authors, AMPARs seem to be responsible for mirror focus development. Therefore, understanding the mechanisms underlying this complex circuit could be useful for stopping or managing the secondary lateralization of seizures. 45 Furthermore, this mechanism may well explain the efficacy of perampanel in bilateral tonic-clonic seizures and may be extremely relevant during SE to prevent seizureinduced brain damage.
| AMPA RECEPTOR ANTAGONISTS IN ANIMAL MODELS OF STATUS EPILEPTICUS
The therapeutic potential of AMPAR inhibition has been supported by animal studies in which AMPARs antagonists, such as GYKI52466 and NS1209, have been shown to terminate seizures in models of benzodiazepine-resistant SE 35, [46] [47] [48] (Table 2) . Another AMPA receptor antagonist that may confer benefits in this setting is perampanel, 49 which has been approved by the European Medicines Agency and the US Food and Drug Administration as an adjunctive treatment both for partial-onset seizures, with or without secondary generalization, and primary generalized tonic-clonic seizures in patients aged ≥12 years. Generally, the most efficacious doses were associated with sedation and dizziness; no other adverse events were reported (blood pressure or blood tests). 16, 50, 51 The effect of AMPAR antagonists has been evaluated in different experimental models of SE (kainate-, amygdala electrical stimulation-, and pilocarpine-induced) showing a dose-dependent response in stopping seizures.
Notably, perampanel and GYKI52466 were able to abort SE in rats with severe pilocarpine-induced SE that was resistant to diazepam. Moreover, even if the expression of the AMPAR subunit GluA2 has been found reduced in SE, AMPA receptor antagonists continue to provide efficacy. 35 , 49 Hanada et al 49 have investigated the effects of diazepam (10, 20, or 40 mg/kg), perampanel (1, 2.5, 5, or 8 mg/kg), and GYKI52466 (50 mg/kg) in the lithiumpilocarpine-induced SE rat model. Drug effects were evaluated both at 10 or 30 minutes after seizure onset. Moreover, the coadministration of diazepam (2.5-5 mg/kg) and perampanel (0.5-1 mg/kg) 30 minutes after seizure development was evaluated. Perampanel could block epileptic seizures, with an effective dose 50 (ED 50 ) of 1.7 mg/kg when administered 10 minutes after seizure onset. In addition, this effect was maintained when administered 30 minutes after seizure onset; however, at a lower potency with an ED 50 of 5.1 mg/ kg. Of interest, perampanel at 8 mg/kg immediately stopped seizures at 30 minutes after SE onset in all animals (100% responder rate). Likewise, GYKI52466 at 50 mg/kg showed efficacy to reduce seizures in this animal model when injected at 30 minutes after SE, as it was similarly demonstrated by Rajasekaran et al. 35 At odds, diazepam was only effective at 10 minutes after SE onset with an ED 50 of 30 mg/kg, whereas at 30 minutes it lost its efficacy, indicating that pharmacoresistance to benzodiazepine already arose at this early time point in this animal model. Of interest, Hanada et al 49 also reported that seizures were consistently terminated in the lithium-pilocarpine rat model by the coadministration of low doses of diazepam (5 mg/kg) and perampanel (1 mg/kg), similar to the efficacy observed at this time point with perampanel 8 mg/kg alone, suggesting potential synergistic effects that may reduce the required therapeutic dose of perampanel in the presence of diazepam, and potentially conferring improved safety outcomes. In conclusion, this study proves both the efficacy of perampanel and the fast development of pharmacoresistance to benzodiazepines in the lithium-pilocarpine-induced SE model in rats. As to perampanel, these results indicate that its potency fades over time as demonstrated by the ED 50 value increase observed at 30 minutes. This potency reduction might indicate a potential alteration in the system, which may lead to a reduction in efficacy at later time points. These latter experiments should be performed to understand whether for AMPA antagonists, pharmacoresistance may also develop over time. Based on the study conducted by Russo et al, 39 it can be speculated that the potency reduction of perampanel over time could be linked to an altered level of AMPAR subunits expression (see above). However, this reduction remains to be demonstrated and characterized. Recently, the effects of talampanel were also assessed against kainate-induced SE in neonatal (P7) rats. In detail, the treatment with talampanel (5 and 10 mg/kg, ip) 5 minutes after kainate (4 mg/kg, ip) administration delayed the onset of SE and tonic extension. Moreover, talampanel at 10 mg/kg but not GYKI 52466 (20 or 50 mg/kg, ip), a noncompetitive AMPAR antagonist, when administered 10 minutes after kainate, was able to block the behaviorally ongoing SE; notably, no electroencephalography (EEG) recordings were performed in these experiments and therefore there is a limitation in the value of the results obtained. The effect observed was time-dependent, in fact, seizures reappear after about 36 minutes. According to the authors, talampanel is effective for counteracting convulsions in the kainate model of neonatal SE; however, based on the pharmacokinetic profile of talampanel, multiple administrations are needed to observe neuroprotective action. In fact, even though the half-life of talampanel in humans is 3-4 hours, this might be very different in neonatal rats. Likewise, the authors have hypothesized that multiple injections of GYKI 52466 may be needed to stop SE in these animals. In fact, as already demonstrated, GYKI 52466 can protect animals against kainate-induced SE only after multiple injections. 52 Finally, Pitkanen et al 46 have compared the efficacy and the neuroprotective properties of NS1209 with those of diazepam (DZP) in adult rats, in which SE was elicited by electrical amygdala stimulation or subcutaneous injection of kainate. In this study, NS1209 treatment (10-50 mg/kg; ip or iv, followed by another dose of 4 or 5 mg/kg/h iv, for 2-24 hours) started either 2 or 3 hours after SE, has shown a more prominent anticonvulsant activity than DZP (20 mg/kg, ip, and another injection of 10 mg/kg 6 hours later). Moreover, NS1209 treatment showed neuroprotective effects preventing SE-induced hippocampal neuronal death. However, the neuroprotective effect of NS1209 was lower than that of DZP. Although these studies provide evidence that AMPAR antagonists could represent a potential treatment in the armamentarium of drugs used to manage SE, it
has not yet been demonstrated, if the neuroprotective effects of AMPAR antagonists, such as NS1209, are secondary to their ability to reduce the abnormal excitatory neuronal activity during SE. 46 According to these preclinical studies, the current therapeutic armamentarium of SE could be expanded by drugs targeting AMPARs. Among these compounds deserve attention both the competitive AMPA antagonists including NS1209 as well as the noncompetitive AMPAR antagonist perampanel, which have both demonstrated efficacy to decrease and terminate electrographic SE. Moreover, these compounds have been administered safely in animal models undergoing SE. However, competitive NS1209 is water soluble and its brain permeability is likely too slow, while perampanel is insoluble in water and an injectable formulation does not yet exist. 16, [53] [54] [55] 4 | AMPA RECEPTOR
ANTAGONISTS FOR STATUS EPILEPTICUS IN HUMANS: PRELIMINARY EVIDENCE
Most potential AEDs are initially evaluated for their ability to prevent recurrence of seizure in patients with chronic partial epilepsy. Conversely, clinical studies in SE are performed only exceptionally prior to regulatory approval. An exception to this rule, is represented by a clinical trial (phase II) aiming to evaluate the effect of the AMPA receptor antagonist NS1209 in refractory SE. 56 This was designed as a prospective, randomized, multicenter trial for the treatment of refractory SE. The primary objective of the study was to evaluate the effects of this novel drug, NS1209, compared to a standard treatment (phenytoin/valproate). However, the study unfortunately failed to reach the enrollment target, with only 28 patients recruited and 14 treated with the drug. Therefore, the study was insufficiently powered to detect any statistically significant difference between the 2 treatment groups. Even if developing prospective randomized controlled clinical trials in SE can be challenging, 57, 58 in recent years, clinical trials have been conducted successfully in this condition and, in particular for SE stage I, these have increased scientific knowledge. 59 Randomized controlled trials for treatment of refractory and superrefractory SE are desirable, but difficult to conduct. Recently, a phase 1/2 trial of neurosteroids in superrefractory status demonstrated safety and tolerability, but randomized controlled data failed to demonstrate efficacy. 60 Considering these difficulties, real world data obtained from postmarketing experience, as well as data from large multicenter registries, can be of interest for evaluating the potential effectiveness of AEDs in the treatment of SE. Of course, this kind of study gives a low level of evidence when compared with clinical trials; nevertheless they can generate preliminary data that could be further tested in prospective controlled studies. Two case reports on the use of perampanel in patients with SE are present in literature, suggesting a possible role of perampanel in seizure termination in patients with RSE (one of them in a postanoxic brain insult). 61, 62 However, in this context, after many different and sometime chaotic pharmacological trials, the relationship of seizure termination and drug action is not always straightforward, and additional effect of previous medications could not be completely ruled out. More recently, 2 retrospective, single-center studies on the effects of perampanel on refractory SE have been published 54, 63 (Table 3) .
Both studies were retrospective small case series and evaluated the effects of perampanel as add-on treatment in severe cases of refractory SE. Overall, 22 SE episodes were reported, in old patients (mean age over 70 years), with acute symptomatic forms of SE. Regarding the type of status, nonconvulsive status epilepticus (NCSE) (19 of 22 episodes) was the prevalent form of SE in which perampanel was administered. Considering the overall success rate in terminating SE, 6 of 22 SE episodes were considered terminated by perampanel administration (27.3% success rate, within 24 hours from administration or dose increase without changes in other medications). No adverse effects related to perampanel were reported regarding cardiorespiratory changes or laboratory parameter. Rohracher et al, 63 who investigated RSE in an intensive care unit setting, did not report the need to increase doses of pressor agents after perampanel administration in patients who were catecholamine dependent. Moreover, AED plasma concentration levels were not affected by perampanel administration, whereas perampanel plasmatic levels were not assessed in both studies.
Regarding the efficacy, the overall response rate was moderate. However, several aspects for both studies should be considered. (1) The median initial dose was 4-6 mg, titrated up to a maximum dose of 12 mg in 1-2 days. This dose might be low compared to the preclinical SE models. In rats, the effective dose at which SE was terminated in 50% of the animals (ED 50 ) 30 minutes after SE onset was 5.1 mg/kg 49 ; considering that perampanel ED 50 in other animal models ranges between 0.5 and 1.6 mg/kg, it is reasonable to believe that high doses are needed to terminate SE also in patients. (2) Perampanel was administered intravenously in rats, whereas in humans, being that the intravenous formulation was not yet available, the oral formulation was administered via nasogastric tube. This is further complicated by the altered absorption due to the clinical condition of these patients. ( 3) The timing of administration was started late considering the beginning of SE, on average 1.5 and 3.5 days in the 2 studies, which might have been too late in the course of SE. Namely, the subcellular changes that lead to self-sustaining seizure activity are only partly discovered [7] [8] [9] [10] 35 and they are not fully understood at such an advanced stage of SE. These factors might contribute to the modest success of perampanel, when given at the late stages of SE. Some previous studies on the add-on of other new AEDs in patients with RSE/SRSE show that the efficacy could be low when the administration is so late with respect with SE onset and could be extremely variable depending on the characteristics of the studied population. The use of lacosamide in patients with RSE shows extremely different results in seizure termination varying from 0% 64 to 100%, 65 to 51%, 15 and 30%. 66 Finally, given the pharmacokinetic properties of perampanel, further considerations should be made. Peak plasma concentrations of perampanel have been observed between 15 minutes to 2 hours after oral administration. 53 Perampanel distributes into the body tissue, and the remaining plasma fraction has a terminal half-life of about 105 hours. Peak plasma concentrations, as well as plasma levels, increase for about 14 days if the initial daily dose is maintained. Because of these effects, if 6 mg is administered for the first time in a normal weight patient, there will probably be only a time frame of a few hours in which the plasma concentration is at a therapeutic level. Conversely, with repetitive administrations, the plasma concentration will increase considerably. Therefore, the effectiveness of perampanel in terminating an SE should increase from day to day, and it may play a considerable role in the termination of a refractory SE, even later than 72 hours after the first administration. These considerations can be relevant for setting the time point in which the success or failure of treatment with oral perampanel must be evaluated. Setting 24 hours postadministration as cutoff period for the evaluation of the success rate could indeed be too early. On the other hand, if taking the preliminary data of both studies and these considerations to increase the effectiveness of perampanel in terminating a refractory SE in a shorter period of time, it might be useful to start with loading doses higher than 6 mg to attain higher and more appropriate plasma/brain levels or dose intervals shorter than 24 hours. Unfortunately, however, safety data for such dose regimen are lacking and this should be carefully monitored during any attempt.
| CONCLUSIONS
In the last 10 years, the role of AMPARs during and after SE has become clearer, and it is now widely accepted that these early changes occur in the initial stages and probably contribute both to the maintenance of SE and to its refractoriness to treatment. The relevance of this involvement is confirmed indirectly by the high efficacy of AMPAR antagonists in preclinical models of SE including those refractory to benzodiazepine. Considering the problems in running clinical trials for SE, the availability of perampanel as a noncompetitive AMPAR antagonist is making it possible to test its potential effects in this field, at least against RSE. In fact, despite the existence of only limited data in humans, the use of AMPAR antagonists in patients with SE seems to be promising. AMPAR antagonists and perampanel, in particular, could become a new therapeutic option in patients with established SE, especially when the first trials with second-line agents are failed or probably even better after the failure of benzodiazepines as a second-line option. In the future, it will be important to develop an injectable perampanel formulation and to test its efficacy in SE treatment with appropriate clinical trials; although, it would be important to truly understand whether acting contemporary on GABA A and AMPA receptors is synergistic, since, based on the knowledge that both receptors are early involved in SE, this may represent a good combinatorial initial treatment reducing the number of patients entering refractory status and preventing the development of brain pathological alterations sustaining SE itself.
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